Alejandro Bertolet, PhD

Mechanistic models can help us understand why hadrons kill cells more effectively than photons. We used ChronoRepair, an agent-based model that tracks individual double-strand breaks (DSB) through detection, repair, and cell-fate decisions, to identify which...

Preclinical studies combining radiation with gadolinium-based AGuIX nanoparticles show potent radiosensitization effect. However, physics simulations to date show a lack of macroscopic dose enhancement. We address this by shifting from absorbed dose (D) to mi...

This educational session will address why dosimetry is central to modern radiopharmaceutical therapy. It will highlight how fixed-activity approaches emerged historically and why they are increasingly insufficient in the context of therapeutic precision, safe...

This educational session will address why dosimetry is central to modern radiopharmaceutical therapy. It will highlight how fixed-activity approaches emerged historically and why they are increasingly insufficient in the context of therapeutic precision, safe...

This session will present a structured, educational overview of how to perform patient-specific dosimetry in radiopharmaceutical therapy, using AAPM TG-381 as a reference framework. The first part will walk through generalizable dosimetry workflows—from imagi...

Current Y-90 radioembolization (RE) standard dosimetry assumes homogeneous microsphere distribution, ignoring patient-specific vasculature heterogeneity. We developed a framework to reproduce and augment patient-specific hepatic vascular models from cone-beam...

To develop a fast and scalable computational framework for estimating DNA damage induced by X-ray irradiation while retaining track-structure fidelity and reducing computational cost.

Clinical Trials Specialty Program

Interactive, educational, hands-on session (60 min total). The first part focuses on participant interaction with the web demo; the second part provides an expert synthesis of results. Emphasis is on building intuition rather than promoting a single workflow....

Combining external-beam radiation therapy (EBRT) with radiopharmaceutical therapy (RPT) is gaining momentum as the two modalities complement each other from a radiation-biology perspective. EBRT delivers precise, high-dose radiation to bulky, image-defined le...

Radiopharmaceutical therapy (RPT) is re-shaping how radiation is used to combat cancer since it provides a way to deliver radiation systemically. Due to its impactful clinical applications, RPT has been approved by the FDA to treat patients with metastatic ca...

Personalized dosimetry in radiopharmaceutical therapy (RPT) is gaining strong interest because fixed-activity regimens often fail to capture the large variability in how patients respond to the treatment. Growing evidence shows clear dose–response relationshi...

As precision oncology evolves, the goal is for RPT to be viewed as a bridge between nuclear medicine, radiation oncology and medical oncology for the benefit of patients with cancer. However, challenges remain related to items, such as “turf wars” between dep...

Interest in Y-90 dosimetry for liver radioembolization has grown rapidly as clinical evidence demonstrates a clear relationship between absorbed dose, treatment response, and toxicity. Historically, activity prescriptions were based on simplified empirical or...

At the subcellular scale, Monte Carlo track-structure (MCTS) has demonstrated good accuracy for modeling the initial radiation-induced biological damage by providing a detailed characterization of the spatiotemporal complex structure of ionizing radiation. At...

This session will present a structured debate on single versus multiple timepoint dosimetry in radiopharmaceutical therapy, highlighting both technical and clinical perspectives. A speaker from the nuclear medicine/imaging side will discuss the benefits and r...

This session will focus on the specific considerations involved in clinical trials of alpha-particle radiopharmaceutical therapies. Unlike beta emitters, alpha-emitter therapies bring unique characteristics, short particle range, high linear energy transfer,...